

1168. J Natl Cancer Inst. 2016 Jan 28;108(6):djv403. doi: 10.1093/jnci/djv403. Print
2016 Jun.

HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers 
in 3680 Patients.

Castellsagué X(1), Alemany L(1), Quer M(1), Halec G(1), Quirós B(1), Tous S(1),
Clavero O(1), Alòs L(1), Biegner T(1), Szafarowski T(1), Alejo M(1), Holzinger
D(1), Cadena E(1), Claros E(1), Hall G(1), Laco J(1), Poljak M(1), Benevolo M(1),
Kasamatsu E(1), Mehanna H(1), Ndiaye C(1), Guimerà N(1), Lloveras B(1), León
X(1), Ruiz-Cabezas JC(1), Alvarado-Cabrero I(1), Kang CS(1), Oh JK(1),
Garcia-Rojo M(1), Iljazovic E(1), Ajayi OF(1), Duarte F(1), Nessa A(1), Tinoco
L(1), Duran-Padilla MA(1), Pirog EC(1), Viarheichyk H(1), Morales H(1), Costes
V(1), Félix A(1), Germar MJ(1), Mena M(1), Ruacan A(1), Jain A(1), Mehrotra R(1),
Goodman MT(1), Lombardi LE(1), Ferrera A(1), Malami S(1), Albanesi EI(1), Dabed
P(1), Molina C(1), López-Revilla R(1), Mandys V(1), González ME(1), Velasco J(1),
Bravo IG(1), Quint W(1), Pawlita M(1), Muñoz N(1), de Sanjosé S(1), Xavier Bosch 
F(1); ICO International HPV in Head and Neck Cancer Study Group.

Collaborators: Albanesi EI, Erzi S, Miciquevich S, Nessa A, Rahman N, Kamal M,
Ahmed F, Viarheichyk H, Valeriy S, Searhei A, Claros E, Vega PA, Mollinedo J,
Vargas PS, Márquez LM, Iljazovic E, Prado R, Molina C, Muñoz R, Rodriguez X,
Guerrero M, Leiva V, Olave E, Ramis C, Toro V, Cadena E, Murillo R, Suárez GA,
Pinzón CE, González ME, Aruachan S, Torregrossa M, Mandys V, Laco J, Tinoco L,
Cabezas JC, Camacho F, Quinto R, Jaramillo L, Costes V, Garre R, Ramayl AS,
Tommasino M, Gheit T, Pawlita M, Halec G, Holzinger D, Fend F, Biegner T, Kestler
E, Lombardi LE, Salic O, Marroquin S, Argueta V, Marroquin S, Guerra W, Mérida
HM, Tala MM, Ferrera A, Muñoz FD, Molinero M, Toledo L, Calix ES, Padilla NS,
Jain A, Giri SK, Bhalla M, Patel B, Sarma PS, Mehrotra R, Singh M, Benevolo M,
Covello R, Spriano G, Pichi B, Donà MG, Shin HR, Oh JK, Suh JI, Kim DC, Chang-Suk
K, Alvarado-Cabrero I, Viveros PA, Padilla MA, Ceballos ME, Magaña-León C,
López-Revilla R, Oros C, Padilla MA, Viveros PA, Ceballos ME, Abdulkareem FB,
Daramola AO, Anunobi CC, Anorlu RU, Ajayi OF, Malami S, Umar AB, Kasamatsu E,
Cubilla AL, Perrota F, Figueredo S, Domingo EJ, Luna JT, Germar MJ, Fernandez AM,
Castro CZ, Balacuit R, Szafaroswski T, Felix A, Soares JM, Ndiaye C, Ndiaye N,
Mendes V, de Médecine F, Diop UC, Poljak M, Kocjan BJ, Gale N, Maver PJ, Lloveras
B, Martín G, Alós L, Velasco J, Alejo M, Mulero A, León X, Quer M, García-Rojo M,
López LG, Gil MC, Alemany L, Bosch FX, Bravo IG, Camón V, Castellsagué X, Clavero
O, de Sanjosé S, Esteban A, Florencia Y, Klaustermeier J, Mena M, Muñoz N, Quirós
B, Rajo C, Tous S, Vergara M, Quint WG, Geraets DT, Guimerà N, Meijer CJ,
Usubutun A, Ruacan A, Ruacan A, Kitchener H, Hall G, Wilson G, Hisham M, Rapozo
D, Shelley W, Sean J, Cozen W, Hernández BY, Lynch C, Olson DB, Selk FR, Goodman 
MT, Pirog EC, Dabed P, Meijer CJ, Tommasino M, Pawlita M, Quint W, Alós L.

Author information: 
(1)Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO),
IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain (XC, LAle, BQ, ST, OC, MM,
IGB, SdS, FXB); CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
(XC, LAle, SdS); Hospital Sant Pau, Barcelona, Spain (MQ, XL); German Cancer
Research Center (DKFZ), Heidelberg, Germany (GHale, DH, MPa); Hospital Clínic,
University of Barcelona, Spain (LAlò); Department of Pathology, University
Hospital Tuebingen, Tuebingen, Germany (TB); Department of Otorhinolaryngology,
Faculty of Medicine and Dentistry, Warsaw Medical University, Czerniakowski
Hospital, Warsaw, Poland (TS); Hospital General de l'Hospitalet, L'Hospitalet de 
Llobregat, Barcelona, Spain (MA); Instituto Nacional de Cancerología, Bogotá,
Colombia (ECa, NM); Universidad Nacional de Colombia, Bogotá, Colombia (ECa);
Insituto Oncológico del Oriente Boliviano (IOOB), Laboratorio Privado de
Patología Oncos, Santa Cruz, Bolivia (ECl); Manchester Royal Infirmary,
Manchester, UK (GHall); The Fingerland Department of Pathology, Charles
University Faculty of Medicine and University Hospital, Hradec Kralove, Czech
Republic (JL); University of Ljubljana, Faculty of Medicine, Institute of
Microbiology and Immunology, Ljubljana, Slovenia (MPo); Regina Elena National
Cancer Institute, Rome, Italy (MB); Instituto de Investigaciones en Ciencias de
la Salud, Universidad Nacional de Asunción, Asunción, Paraguay (EK); Institute of
Head and Neck Studies and Education, University of Birmingham, Birmingham, UK
(HMe); Department of Social and Preventive Medicine, Université de Montréal,
Montreal, Canada (CN); DDL Diagnostic Laboratory, Rijswijk, the Netherlands (NG, 
WQ); Pathology Department, Hospital del Mar IMIM, Universitat Pompeu Fabra,
Barcelona, Spain (BL); Laboratorio Clínico y Molecular, Hospital SOLCA,
Guayaquil, Ecuador (JCRC); Hospital de Oncología Centro Médico Nacional Siglo
XXI, IMSS Mexico, D.F., Mexico (IAC); Yeouido St. Mary's

BACKGROUND: We conducted a large international study to estimate fractions of
head and neck cancers (HNCs) attributable to human papillomavirus (HPV-AFs) using
six HPV-related biomarkers of viral detection, transcription, and cellular
transformation.
METHODS: Formalin-fixed, paraffin-embedded cancer tissues of the oral cavity
(OC), pharynx, and larynx were collected from pathology archives in 29 countries.
All samples were subject to histopathological evaluation, DNA quality control,
and HPV-DNA detection. Samples containing HPV-DNA were further subject to HPV
E6*I mRNA detection and to p16(INK4a), pRb, p53, and Cyclin D1
immunohistochemistry. Final estimates of HPV-AFs were based on HPV-DNA, HPV E6*I 
mRNA, and/or p16(INK4a) results.
RESULTS: A total of 3680 samples yielded valid results: 1374 pharyngeal, 1264 OC,
and 1042 laryngeal cancers. HPV-AF estimates based on positivity for HPV-DNA, and
for either HPV E6*I mRNA or p16(INK4a), were 22.4%, 4.4%, and 3.5% for cancers of
the oropharynx, OC, and larynx, respectively, and 18.5%, 3.0%, and 1.5% when
requiring simultaneous positivity for all three markers. HPV16 was largely the
most common type. Estimates of HPV-AF in the oropharynx were highest in South
America, Central and Eastern Europe, and Northern Europe, and lowest in Southern 
Europe. Women showed higher HPV-AFs than men for cancers of the oropharynx in
Europe and for the larynx in Central-South America.
CONCLUSIONS: HPV contribution to HNCs is substantial but highly heterogeneous by 
cancer site, region, and sex. This study, the largest exploring HPV attribution
in HNCs, confirms the important role of HPVs in oropharyngeal cancer and
drastically downplays the previously reported involvement of HPVs in the other
HNCs.

© The Author 2016. Published by Oxford University Press. All rights reserved. For
Permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/jnci/djv403 
PMID: 26823521  [Indexed for MEDLINE]
